Report Publication Announcement • Apr 25, 2025
Report Publication Announcement
Open in ViewerOpens in native device viewer
Lure (France) April 24th 2025

On 24 April 2025, Vetoquinol filed its 2024 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format).
The 2024 Universal Registration Document in ESEF and PDF formats (reproduction of the official version of the Universal Registration Document in ESEF format) is available to the public under the conditions provided by applicable regulations and may be consulted on the "Investors" page of the Vetoquinol laboratory website (www.vetoquinol.com), in the "Regulated Information" section. It is also available on the AMF's website (www.amffrance.org).
The 2024 Universal Registration Document includes:
Next publication: sales 1st quarter 2025, April 24, 2025 after market close
Vetoquinol is a leading international player in animal health, with operations in Europe, the Americas and Asia/Pacific.
Independent and a pure player, Vetoquinol innovates, develops and markets veterinary medicines and non-medicated products for farm animals (cattle, pigs) and companion animals (dogs, cats).
Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio and acquisitions in high-potential territories ensure hybrid growth for the Group. At December 31, 2024, Vetoquinol employed 2,501 people.
Vetoquinol has been listed on Euronext Paris since 2006 (mnemonic code: VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.
FOR MORE INFORMATION, CONTACT:
VETOQUINOL
Investor Relations Fanny Toillon Tel.: +33 (0)3 84 62 59 88 [email protected]

VETOQUINOL Magny-Vernois 70200 Lure - France
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.